Nykode Therapeutics Reports First Quarter 2025 Earnings

Simply Wall St · 05/30 05:50

Nykode Therapeutics (OB:NYKD) First Quarter 2025 Results

Key Financial Results

  • Net loss: US$1.44m (loss narrowed by 90% from 1Q 2024).
earnings-and-revenue-history
OB:NYKD Earnings and Revenue History May 30th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Portfolio Valuation calculation on simply wall st

Nykode Therapeutics Earnings Insights

Looking ahead, revenue is expected to decline by 113% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 15%.

Performance of the market in Norway.

The company's shares are down 29% from a week ago.

Risk Analysis

You should learn about the 3 warning signs we've spotted with Nykode Therapeutics (including 2 which can't be ignored).